An open-label extension study of rufinamide given as adjunctive therapy in patients with refractory partial seizures.
Phase of Trial: Phase III
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Rufinamide (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 11 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Aug 2009 Planned initiation date (Jan 2011) added as reported by ClinicalTrials.gov.
- 11 Aug 2009 Additional lead trial investigator Bibbiani F identified as reported by ClinicalTrials.gov.